Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents

NCT06838000 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

1268

Enrollment

INDUSTRY

Sponsor class

Conditions

Pneumococcal Infections

Interventions

BIOLOGICAL: PCV21
BIOLOGICAL: 20vPCV

Sponsor

Sanofi Pasteur, a Sanofi Company